Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment by harnessing the immune system to target tumors. However, resistance to ICB therapy remains a significant challenge. This Research Topic aims to present the latest research on novel strategies and approaches to overcome resistance to ICB therapy. By understanding the underlying mechanisms and exploring innovative interventions, we strive to enhance the effectiveness and durability of responses to ICB therapy, ultimately improving patient outcomes.
This Research Topic brings together researchers, clinicians, and industry experts to share their latest findings and advancements in overcoming resistance to ICB therapy. The following subthemes are particularly welcome:
1. Predictive Biomarkers of Response and Resistance: This topic focuses on identifying predictive biomarkers of response and resistance to ICB therapy. Studies investigating potential genomic, transcriptomic, proteomic, or immune profiling markers associated with treatment outcomes are encouraged. Additionally, novel technologies or methodologies for biomarker discovery and validation will be featured.
2. Immunomodulatory Interventions: The development of novel immunomodulatory interventions to overcome resistance and enhance the efficacy of ICB therapy. Studies investigating new immune checkpoint inhibitors, agonists, co-stimulatory molecules, immunomodulatory antibodies, or immune modulators will be featured. Additionally, advancements in the field of bi-specific antibody, immunocytokines and adoptive cell therapy will be considered.
3. Mechanisms and Interventions in the Tumor Microenvironment (TME): This topic explores the role of the TME in ICB resistance. Studies investigating the immunosuppressive components within the TME and strategies to overcome immunosuppression will be included. Additionally, the impact of microbiota, stromal cells, and metabolic reprogramming on treatment response will be addressed.
4. Translational and Clinical Advancements: This topic showcases translational and clinical research studies focusing on overcoming resistance to ICB therapy. Clinical trials exploring new treatment strategies, predictive biomarkers, resistance mechanisms, or innovative interventions will be included. Real-world evidence studies evaluating the effectiveness of interventions in clinical practice are also welcome.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords:
Immune checkpoint blockade, ICB, cancer treatment, ICB therapy, Immune Checkpoint, Tumor Microenvironment, TME, Immunomodulatory Interventions, Combination Approaches, Predictive Biomarkers
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment by harnessing the immune system to target tumors. However, resistance to ICB therapy remains a significant challenge. This Research Topic aims to present the latest research on novel strategies and approaches to overcome resistance to ICB therapy. By understanding the underlying mechanisms and exploring innovative interventions, we strive to enhance the effectiveness and durability of responses to ICB therapy, ultimately improving patient outcomes.
This Research Topic brings together researchers, clinicians, and industry experts to share their latest findings and advancements in overcoming resistance to ICB therapy. The following subthemes are particularly welcome:
1. Predictive Biomarkers of Response and Resistance: This topic focuses on identifying predictive biomarkers of response and resistance to ICB therapy. Studies investigating potential genomic, transcriptomic, proteomic, or immune profiling markers associated with treatment outcomes are encouraged. Additionally, novel technologies or methodologies for biomarker discovery and validation will be featured.
2. Immunomodulatory Interventions: The development of novel immunomodulatory interventions to overcome resistance and enhance the efficacy of ICB therapy. Studies investigating new immune checkpoint inhibitors, agonists, co-stimulatory molecules, immunomodulatory antibodies, or immune modulators will be featured. Additionally, advancements in the field of bi-specific antibody, immunocytokines and adoptive cell therapy will be considered.
3. Mechanisms and Interventions in the Tumor Microenvironment (TME): This topic explores the role of the TME in ICB resistance. Studies investigating the immunosuppressive components within the TME and strategies to overcome immunosuppression will be included. Additionally, the impact of microbiota, stromal cells, and metabolic reprogramming on treatment response will be addressed.
4. Translational and Clinical Advancements: This topic showcases translational and clinical research studies focusing on overcoming resistance to ICB therapy. Clinical trials exploring new treatment strategies, predictive biomarkers, resistance mechanisms, or innovative interventions will be included. Real-world evidence studies evaluating the effectiveness of interventions in clinical practice are also welcome.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords:
Immune checkpoint blockade, ICB, cancer treatment, ICB therapy, Immune Checkpoint, Tumor Microenvironment, TME, Immunomodulatory Interventions, Combination Approaches, Predictive Biomarkers
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.